BEAM
Beam Therapeutics Inc.+$0.46 (1.78%) At close $26.33 · Today
☾After Hours +$0.08 (0.31%) Nov 3, 7:59 PM ET
About BEAM
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Company
- Headquarters
- Cambridge, MA
- Employees
- 540 (2026)
- Listed
- Feb 6, 2020
- Exchange
- Nasdaq
- Website
- beamtx.com
- SEC industry
- Biological Products, (no Diagnostic Substances)
- Cylvex sector
- Health Care · Biotech
Biotech
- Market cap #28 of 146
- P/B #57 of 131
Ranked highest first among stocks Cylvex covers.
- AMGNAmgen Inc$249.4B-0.90%
- GILDGilead Sciences Inc$207.7B-1.68%
- MRNAModerna Inc$91.20B+3.45%
- ARGXargenx SE$56.67B+2.99%
- RVMDRevolution Medicines, Inc.$41.63B+3.22%
Financial summary
Related companies
About
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.